“…However, the decreased activity of KAF156 is not only regulated by the mutation of PfCARL alone; mutation in few other genes is also affecting the role of KAF156 . Currently, the drug is in the pipeline of clinical trials in combination with lumefantrine (Ashley & Phyo, ; Phillips et al., ). The imidazolopiperazines target multiple stages of the parasite: asexual stage, sexual stage, and liver stage schizonts (Burrows et al., ; Gamo, ; Kuhen et al., ; Leong et al., ; Phillips et al., ; Phyo & Seidlein, ; Satish et al., ; White et al., ).…”